Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-10-20
2009-11-24
Chunduru, Suryaprabha (Department: 1637)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S006120, C435S091200, C536S024330
Reexamination Certificate
active
07622566
ABSTRACT:
A method for double-stranded DNA purification, by which a solution containing DNA in a mixture with other components is passed over a support on which is covalently coupled an oligonucleotide capable of hybridizing with a specific sequence present on the DNA to form a triple helix.
REFERENCES:
patent: 4766072 (1988-08-01), Jendrisak et al.
patent: 5164491 (1992-11-01), Froehler et al.
patent: 5399676 (1995-03-01), Froehler
patent: 5401632 (1995-03-01), Wang et al.
patent: 5476925 (1995-12-01), Letsinger et al.
patent: 5478893 (1995-12-01), Ghosh et al.
patent: 5482836 (1996-01-01), Cantor et al.
patent: 5484908 (1996-01-01), Froehler et al.
patent: 5591841 (1997-01-01), Ji et al.
patent: 5665541 (1997-09-01), Miller et al.
patent: 5800984 (1998-09-01), Vary
patent: 6287762 (2001-09-01), Crouzet et al.
patent: 6319672 (2001-11-01), Crouzet et al.
patent: 6977174 (2005-12-01), Crouzet et al.
patent: 7279313 (2007-10-01), Soubrier
patent: 7364894 (2008-04-01), Soubrier
patent: WO 89/02436 (1989-03-01), None
patent: WO 90/09393 (1990-08-01), None
patent: WO 90/10716 (1990-09-01), None
patent: WO 92/09705 (1992-06-01), None
patent: WO 92/11390 (1992-07-01), None
patent: WO 92/13963 (1992-08-01), None
patent: WO 92/18647 (1992-10-01), None
patent: WO 93/00352 (1993-01-01), None
patent: WO 93/13220 (1993-07-01), None
patent: WO 94/00600 (1994-01-01), None
patent: WO 94/17086 (1994-08-01), None
patent: WO 96/18744 (1996-06-01), None
patent: WO 2004/108167 (2004-12-01), None
Ausubel et al.,Current Protocols in Molec. Biol., Supp. 27, 1.7.1-1.7.15, 1994.
Ausubel et al.,Current Protocols in Molec. Biol., Supp. 15, 1.6.1-1.6.10, 1991.
Sambrook et al., “Extraction and Purification of Plasmid DNA,” Laboratory Manual, 1.21-1.52, 1987.
He et al.,Genetic Analysis Techniques&Applications, 8(3):107-110, 1991.
Ito et al.,Proc. Nat'l. Acad. Sci. USA, 89:495-498, 1992.
Jarrett,Journal of Chromatography, 618(8):315-339, 1993.
Kiessling et al.,Biochemistry, 31:2829-2834, 1992.
Duval-Valentin et al.,Proc. Nat'l. Acad. Sci., USA, 89:504-508, 1992.
Jayasena et al.,Nucleic Acids Research, 20(20):5279-5288, 1992.
Carrière et al., “Optimization of plasmids for gene delivery,” STP Pharma Sciences, 2001, vol. 11 No. 1, pp. 5-10.
Presentation entitled “Gene Therapy for Ischemic Disease,” by Beatrice Cameron, Sep. 23-27, 1998, Cold Spring Harbor Laboratory, New York.
Presentation entitled “FGF-1 Gene Delivery: Preliminary Clinical Results in Peripheral Vascular Disease,” by Richard Pilsudski, Third Annual Angiogenesis Mini-Summit, New Orleans, La., Nov. 11, 2000.
Presentation entitled Arteriopathie des Membres Inferieurs: Quoi de neuf 2001 Therapie Genique, by Richard Pilsudski, Journees Internationales d'Angeiologie, Paris, Jan. 12-13, 2001.
Presentation entitled “Strategies for Clinical Applicationi of Angiogenesis-Myogenesis Research,” by Richard Pilsudski, 7thLocal Drug Delivery Meeting and Cardiovascular Course on Radiation and Molecular Strategies, Geneva, Switzerland, Jan. 25-27, 2001.
Presentation entitled Angiogenesis: Promoting Angiogenesis: Angiogenesis Gene Therapy for Peripheral Vascular Disease, by Richard Pilsudski, Institut Pasteur Euroconferences, Paris, Mar. 8-9, 2001.
Presentation entitled “Large-Scale Purification of Plasmid DNA b Triplex Affinity Chromotography,” Francis Blanche, Recovery X, Cancun, Jun. 3-8, 2001.
Presentation entitled “Therapeutic Angiogenesis in Peripheral Vascular Disease—Final Results of the Phase I Trial on FGF-1 Gene Delivery,” by Richard Pilsudski, Angiogenesis & DMR, Washington., Jun. 21-22, 2001.
Presentation entitled Purification of Plasmid DNA by Triplex Affinity Chromotography, by Francis Blanche, Downstream Processing of Nucleic Acids, Sep. 17-18, 2001.
Presentation entitled Therapeutische Angiogenese: Clinical Results of NV1FGF Gene Therapy in Chronic Limb Ischemia, by Richard Pilsudski, Angio 2001, Nov. 29-Dec. 1, 2001, Bem.
Presentation entitled “pCOR Gene Therapy Plasmid: Improvements of Existing Technology,” by Fabienne Soubrier, ESGT, approximate date Oct. 13, 2002.
Presentation entitled “Final Results of a FGF-1 Gene Therapy Clinical Trial in Patients with Critical Limb Ischemia,” by Marie-Helene Francois, 17thInternational Congress on Thrombosis, Oct. 30, 2002, Bologna, Italy.
Presentation entitled A Phase 1 Study to Evaluate the Safety and Biological Activity of Plasmid DNA Encoding FGF1 in Patients with Severe Peripheral Artery Occlusive Disease, by Michael Coleman, Angiogenesis: Gene Therapy of Cardiovascular Diseases with Angiogenic Growth Factors, SMI, Feb. 17-18, 2003, The Hatton, London.
Presentation entitled “Quality Control of NV1FGF Plasmid DNA for PAD Gene Therapy,” by Didier Faucher, International Symposium organized by EDQM on Standardization and Quality Control Cell and Gene Therapy Products, EDQM meeting, Feb. 24-25, 2003, Strasbourg.
Faucher et al., “Quality Control of NV1FGF Plasmid DNA for PAD Gene Therapy,” Standardization & QC Cell and Gene Therapy Products, for meeting held Feb. 24-25, 2003, Strasbourg, France.
Talisman™ Brochure, American Heart Association, approximate date Nov. 3, 2003.
Presentation entitled “Large-Scale Production of Plasmids for Gene Therapy,” by Francis Blanche, SMBC, Singapore, Apr. 20, 2004.
Presentation entitled, Treatment of Peripheral Arterial Disease with NV1FGF, Tlaisman™ Trials, by Michael Colemen, ,SMI, May 17-18, The Hatton, London.
Presentation entitled Talisman 105™: IM Injections of NV1FGF in CLI Patients with Planned Amputation, by Iris Baumgartner, American Heart Association, Nov. 8, 2004.
Presentation entitled Gene Therapy for the Treatment of Peripheral Arterial Disease, by Francois Meyer, ESGT, Oct. 28, 2005.
Presentation entitled “Therapeutic Angiogenesis with Intramuscular NV1FGF Improves Amputation-Free Survival in Patients with Critical Limb Ischemia,” by S. Nikol et al., ACC.06 i2 Summit 2006, Mar. 11-14, Atlanta.
Diogo et al., “Chromatography of plasmid DNA,”Journal of Chromatography A, 1069:3-22, 2005.
Ji et al., “Rapid Purification of Double-Stranded DNA by Triple-Helix-Mediated Affinity Capture,”Anal. Chem., 65:1323-1328, 1993.
Wils et al., “Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography,”Gene Therapy, 4:323-330, 1997.
Crouzet Joël
Scherman Daniel
Wils Pierre
Centelion
Chunduru Suryaprabha
Finnegan Henderson Farabow Garrett & Dunner LLP
LandOfFree
Purification of a triple helix formation with an immobilized... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purification of a triple helix formation with an immobilized..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purification of a triple helix formation with an immobilized... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4104005